TMEM174

Across TCGA pan-cancer cohorts, TMEM174 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMEM174 data layer compared with 12 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher TMEM174 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM174 expression acts as an unfavorable survival marker.

LUSC, BLCA, and CESC are the cancer types where TMEM174 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	III,IV	0.079	0.658	<.001	13	view →
BLCA	OS	Median	All	0.229	0.720	.012	9	view →
CESC	OS	Median	All	0.099	0.585	.049	6	view →
STAD	OS	Median	All	0.250	0.729	.034	6	view →
LIHC	OS	Median	All	0.258	0.773	.018	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TMEM174–LUSC (DFS)

Open the LUSC breakdown →